Alliance to Identify Potential Antimicrobials
By Biotechdaily staff writers
Posted on 11 Oct 2002
A risk-sharing collaboration to discover antimicrobial drugs from microorganisms has been announced by bioLeads GmbH (Heidelberg, Germany) and Elitra Pharmaceuticals, Inc. (San Diego, CA, USA). The collaboration will combine the extensive natural products library of bioLeads with Elitra's antimicrobial discovery technologies.Posted on 11 Oct 2002
To identify potential new antibacterial and antifungal drugs, Elitra will contribute proprietary drug targets, related cell-based assays, and high-throughput screening capabilities, while BioLeads will contribute its library of natural products and its chemistry capabilities. Elitra retains the worldwide marketing rights for all collaboration compounds, while agreeing to make milestone payments and royalties to bioLeads for successful programs.
"More than 99% of all soil microorganisms are still unknown and represent the biotechnologic natural resource of the 21st century,” said F. G. Hansske, CEO of bioLeads. "As a highly specialized company producing potential active natural compound libraries from microorganisms, bioLeads provides an extensive unexploited substance pool.”
Related Links:
BioLeads
Elitra
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
.jpg)
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
